Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan,Mohammad Abdul Hannan,Muhammad Shah Alam,Fatema Tuz Zahura Aalpona,Lakshmi Nagendra,Shahjada Selim,Deep Dutta
DOI: https://doi.org/10.1097/md.0000000000038592
IF: 1.6
2024-06-23
Medicine
Abstract:Female sexual dysfunction (FSD) is common, even more common than male sexual dysfunction. There is limited data on the incidence and prevalence of FSD. [ 1 ] The fourth International Consultation on Sexual Medicine consensus statement asserts that, across a variety of assessment methods, the prevalence of women's sexual complaints, regardless of age, is on the order of 40% to 50%. [ 2 ] Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual complaint in women. HSDD is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised, as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. [ 3 ] In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, HSDD has been replaced by Female Sexual Interest/Arousal Disorder, merging arousal and desire disorders. [ 4 ] It is estimated that about one in 10 women have HSDD. The prevalence varies with age; 8.9% of women ages 18 to 44, 12.3% ages 45 to 64, and 7.4% >65 years have HSDD. [ 5 ] Despite its high prevalence, effective pharmacotherapy for HSDD is still limited. Only two medications, flibanserin and bremelanotide, have been approved by the United States Food and Drug Administration (US FDA) for treating HSDD in premenopausal women. Bremelanotide is a melanocortin 3 and 4 receptor agonist, taken as a subcutaneous injection before sexual activity. Flibanserin is a 5-hydroxytryptamine (5-HT) 1A receptor agonist, 5-HT2A antagonist, taken as a bedtime tablet. [ 1 , 5 , 6 ] The US FDA approved flibanserin, supported by findings from 3 randomized placebo-controlled trials involving premenopausal women with HSDD. These trials demonstrated statistically significant enhancements in sexual desire, desire-related distress, and the frequency of satisfying sexual events (SSE) when administered at a dosage of 100 mg (daily at bedtime) compared to a placebo. [ 6 ] Common adverse events of flibanserin include dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. [ 1 , 5 , 6 ] Coadministration of alcohol may increase the incidence of sedation-, hypotension-, and syncope-related adverse events of flibanserin. [ 7 ]
medicine, general & internal